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The conversion of an epithelial cell to a mesenchymal cell 
is critical to metazoan embryogenesis and a deﬁ  ning 
structural feature of organ development. Current interest 
in this process, which is described as an epithelial–
  mesenchymal transition (EMT), stems from its develop-
mental importance and its involvement in several adult 
pathologies. Interest and research in EMT are currently at 
a high level, as seen by the attendance at the recent EMT 
meeting in Vancouver, Canada (October 1–3, 2005). 
The meeting, which was hosted by The EMT International 
Association, was the second international EMT meeting, 
the ﬁ  rst being held in Port Douglas, Queensland, Australia 
in October 2003. The EMT International Association was 
formed in 2002 to provide an international body for those 
interested in EMT and the reverse process, mesenchymal–
epithelial transition, and, most importantly, to bring to-
gether those working on EMT in development, cancer, 
ﬁ  brosis, and pathology. These themes continued during 
the recent meeting in Vancouver.
Discussion at the Vancouver meeting spanned sev-
eral areas of research, including signaling pathway acti-
vation of EMT and the transcription factors and gene 
targets involved. Also covered in detail was the basic cell 
biology of EMT and its role in cancer and ﬁ  brosis, as well 
as the identiﬁ  cation of new markers to facilitate the obser-
vation of EMT in vivo. This is particularly important be-
cause the potential contribution of EMT during neoplasia 
is the subject of vigorous scientiﬁ   c debate (Tarin, D., 
E.W. Thompson, and D.F. Newgreen. 2005. Cancer Res. 
65:5996–6000; Thompson, E.W., D.F. Newgreen, and 
D. Tarin. 2005. Cancer Res. 65:5991–5995).
Deﬁ  ning epithelial–mesenchymal 
transition (EMT)
Historically, epithelial and mesenchymal cells have been identi-
fi  ed on the basis of their unique visual appearance and the mor-
phology of the multicellular structures they create (Shook and 
Keller, 2003). A typical epithelium is a sheet of cells, often one 
cell thick, with individual epithelial cells abutting each other in 
a uniform array. Regularly spaced cell–cell junctions and adhe-
sions between neighboring epithelial cells hold them tightly to-
gether and inhibit the movement of individual cells away from 
the epithelial monolayer. Internal adhesiveness allows an epi-
thelial sheet to enclose a three-dimensional space and provide it 
with structural defi  nition and mechanical rigidity. The epithelial 
sheet itself is polarized, meaning that the apical and basal sur-
faces are likely to be visually different, adhere to different sub-
strates, or have different functions. Mesenchymal cells, on the 
other hand, generally exhibit neither regimented structure nor 
tight intracellular adhesion. Mesenchymal cells form structures 
that are irregular in shape and not uniform in composition or 
density. Adhesions between mesenchymal cells are less strong 
than in their epithelial counterparts, allowing for increased mi-
gratory capacity. Mesenchymal cells also have a more extended 
and elongated shape, relative to epithelial cells, and they pos-
sess front-to-back leading edge polarity. Unlike epithelia, the 
irregular structure of mesenchyme does not allow for rigid 
  to  pological specialization. Moreover, mesenchymal migration is 
mechanistically different from epithelial movement. Epithelial 
cells move as a sheet en block, whereas mesenchymal migration 
is considerably more dynamic. Mesenchymal cells move indi-
vidually and can leave part of the trailing region behind. Elizabeth 
Hay (Harvard University, Boston, MA), who fi  rst described 
the EMT (Hay, 2005), illustrated the fundamental differ  ences 
of such movement in embryogenesis (subtle/controlled) and 
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tumorigenesis (aggressive/uncontrolled) to defi  ne the distinct 
EMT mechanisms at the EMT conference.
Turning an epithelial cell into a mesenchymal cell requires 
alterations in morphology, cellular architecture, adhesion, and 
migration capacity. Commonly used molecular markers for EMT 
include increased expression of N-cadherin and vimentin, 
nuclear localization of β-catenin, and increased production of the 
transcription factors such as Snail1 (Snail), Snail2 (Slug), Twist, 
EF1/ZEB1, SIP1/ZEB2, and/or E47 that inhibit E-cadherin 
production. Phenotypic markers for an EMT include an increased 
capacity for migration and three-dimensional invasion, as well 
as resistance to anoikis/apoptosis. A summary of common EMT 
markers is listed in Table I. Importantly, these developmental 
regulators can induce EMT in a nondevelopmental context and 
thereby have an important role in cancer and fi  brosis.
Signaling pathways in EMT
Much of the meeting highlighted signaling pathways that regu-
late or mediate the EMT, focusing both on refi  nement and ex-
tension of known pathways, but also on the discovery of new 
regulators and novel pathways (Fig. 1). 
One of the fi  rst cell surface receptors identifi  ed that was 
able to stimulate scattering of epithelial cells was the Met recep-
tor tyrosine kinase. Activation of Met by its ligand, hepatocyte 
growth factor, enhances the migration of multiple cell lines in 
vitro, and scattering of cultured multicystic dysplastic kidney 
cells is a classical EMT assay. Morag Park (McGill University, 
Montreal, Quebec, Canada) reported that transgenic mice ex-
pressing wild-type or active variants of Met under the control of 
the mouse mammary tumor virus promoter develop nodal and 
ductal hyperplasia and spontaneous mammary tumors, albeit 
with a long latency period ( 1.5 yr). Park suggested that Met 
cooperates with the Her2/neu oncogene in activating EMT, and 
that the Crk family of SH2 and SH3 adaptor proteins are critical 
in Met-mediated EMT. Crk proteins are highly expressed in 
  human breast tumors, and Park reported that small interfering 
RNA (siRNA) ablation of Crk inhibits Met-dependent cell 
migration and EMT.
Although the Met receptor-mediated signaling results in 
cell scattering, it has not been made clear whether Met signaling 
also has a more permanent effect on the expression or localiza-
tion of some of the effectors of EMT, such as E-cadherin and 
β-catenin. Recent work by Walter Birchmeier (Max Delbruck 
Center, Berlin, Germany) suggests that Met also regulates intra-
cellular localization of β-catenin. β-Catenin has a dual role in 
the EMT; it enhances cell–cell adhesion when bound to cad-
herin complexes in adherens junctions and also functions as a 
transcriptional coactivator upon entry into the nucleus (van Es 
et al., 2003). The ability of β-catenin to enhance cadherin-
  dependent adhesion depends on β-catenin binding to α-catenin 
and on α-catenin binding to the cadherin (Chu et al., 2004). 
Phosphorylation of β-catenin residue Y142 prevents α-catenin 
interaction and enhances the binding of β-catenin to BCL9-2, 
which is the vertebrate homologue of the Drosophila melano-
gaster legless gene (Brembeck et al., 2004). Interaction of 
β-catenin with BCL9-2 enhances nuclear accumulation of both 
proteins, simultaneously decreasing cadherin-mediated adhesion 
and activating catenin target gene transcription. Ectopic BCL9-2 
expression is suffi  cient to induce EMT in cultured cells, and 
siRNA-mediated BCL9-2 inactivation drives the reverse 
  mesen  chymal–epithelial transition (MET). Birchmeier reported 
that Y142 can be phosphorylated by the Met tyrosine kinase, in-
dicating the existence of an EMT activation pathway where Met 
induces β-catenin nuclear translocation by enhancing BCL9-2 
interaction. This pathway satisfactorily links these two well 
known EMT regulators.
Interestingly, Pez/PTPN14, which is a tyrosine phospha-
tase that is frequently mutated in colorectal tumors (Wang et al., 
2004), induces Snail1 expression and can also activate cell 
  migration (Yeesim Khew-Goodall, Hanson Institute, Adelaide, 
Australia). Pez can dephosphorylate β-catenin on tyrosine resi-
dues that regulate its interaction with the adherens junction 
complex, suggesting that Pez mutations contribute to EMT by 
preventing cytoplasmic β-catenin–cadherin interaction and en-
hancing its nuclear translocation. However, Pez overexpression 
in MDCK and MDA-MB468 cells was shown to be suffi  cient to 
Table I. EMT markers
Proteins that increase in abundance
 N-cadherin
 Vimentin
 Fibronectin
 Snail1  (Snail)
 Snail2  (Slug)
 Twist 
 Goosecoid
 FOXC2
 Sox10
 MMP-2
 MMP-3
 MMP-9
 Integrin  αvβ6
Proteins that decrease in abundance
 E-cadherin
 Desmoplakin
 Cytokeratin
 Occludin
Proteins whose activity increases
 ILK
 GSK-3β
 Rho
Proteins that accumulate in the nucleus
  β-catenin
 Smad-2/3
 NF-κβ
 Snail1  (Snail)
 Snail2  (Slug)
 Twist
In vitro functional markers
 Increased  migration
 Increased  invasion
 Increased  scattering
  Elongation of cell shape
  Resistance to anoikisEPITHELIAL–MESENCHYMAL TRANSITION (EMT) • LEE ET AL. 975
cause EMT, and knockdown in zebrafi  sh causes multiple devel-
opmental abnormalities, including aberrant pigmentation and 
craniofacial deformation. These defects are broadly consistent 
with dysfunctional neural crest EMT in the absence of Pez.
Cancer-relevant insights into EGF signaling were pro-
vided by Erik Thompson (University of Melbourne, Melbourne, 
Australia), who has identifi  ed EGF as a novel EMT inducer in 
human breast cancer, as measured by EGF’s ability to decrease 
E-cadherin and increase vimentin production in PMC42 cells. 
Interestingly, EMT may infl  uence the response of certain can-
cers to EGF receptor (EGFR)–targeted therapeutics. John Haley 
(OSI Pharmaceuticals, Melville, NY) presented data showing 
that the sensitivity of nonsmall cell lung cancer cell lines to 
  erlotinib, which is an EGFR-targeted monoclonal antibody, did 
not correlate with EGFR levels, but rather depended on their 
EMT status, with those having undergone EMT showing resis-
tance (Thomson et al., 2005).
An interesting and novel aspect of EGFR signaling was 
presented by Mien-Chie Hung (The University of Texas MD 
Anderson Cancer Center, Houston, TX), who reported that 
EGFR, which is a transmembrane receptor tyrosine kinase, 
complexes with the STAT3 transcription factor in the nucleus 
and can be immunoprecipitated from the EGF-responsive iNos 
promoter (Lo et al., 2005a). The role that promoter-complexed 
EGFR has in EMT is uncertain, but high nuclear EGFR is asso-
ciated with a poor prognosis in breast carcinoma (Lo et al., 2005b). 
The observation that a transmembrane receptor is found in 
functional promoter complexes in the nucleus was one of the 
meeting’s most surprising observations, and it will be of great 
interest to characterize the topological and structural mecha-
nisms through which a membrane receptor enters the nucleus 
and activates transcription (Giri et al., 2005).
TGF-β is a major regulator of EMT and has been im-
plicated in skin cancer development (Zavadil and Bottinger, 
2005). Jiri Zavadil (New York University School of Medicine, 
New York, NY) reported that TGF-β activates EMT through 
Smad-3–dependent activation of the HEY1 gene, a member 
of the Hairy/Enhancer-of-split family of transcriptional re-
pressors. Zavadil used extensive gene expression profi  ling to 
identify HEY1 targets that are important in EMT induction 
(Zavadil et al., 2004). He reported on the profi  ling of EMT in 
the following three different contexts: HaCaT human keratino-
cyte EMT in response to TGF-β, mouse model of aristolochic 
acid nephropathy, and human kidney-proximal tubule cells. 
Satisfyingly, one of these targets is Dishevelled 2 (DVL2), 
which is a gene that regulates EMT by repressing the produc-
tion of Notch, GSK3β, and β-catenin. Another HEY1 target 
seen in all three systems was the polycomb family histone 
methyltransferases EZH1/EZH2, suggesting that TGF-β–
  activated EMT could be controlled through structural histone
modifi  cation. Other TGF-β targets include integrins β4 and α6.
Richard Bates (University of Massachusetts, Worcester, MA) 
reported that the integrin αvβ6 is up-regulated during co-
lon cancer development and highly expressed in metastatic 
samples (Bates, 2005).
Christopher Gebeshuber showed that TGF-β induced 
Smad-2 tyrosine phosphorylation and that TGF-β–induced 
EMT was blocked upon expression of nonphosphorylatable 
Smad-2 mutant, the expression of which inhibited metastases 
formation. Gebeshuber also reported that this mutant had a re-
duced ability to interact with the Tcf–Lef1 transcription factor. 
This suggests that tyrosine phosphorylation of Smad-2 may po-
tentiate Tcf–Lef1 interaction and stimulate both EMT and meta-
static induction. Ali Nawshad (University of Nebraska, Lincoln, 
NE) and Elizabeth Hay reported a similar noncanonical role for 
TGF-β in the EMT of mouse palatal epithelial seam and kidney-
proximal tubule cells. They reported that Smad-2/4 repressed 
E-cadherin transcription through Tcf–Lef1 (Masszi et al., 2004; 
Nawshad et al., 2005).
One of the functions of TGF-β is to stimulate expression 
of ECM proteins. Do ECM proteins initiate EMT? Andre Menke 
(University of Ulm, Ulm, Germany) showed that extracellular 
collagen that is deposited during a fi  brotic disease can be an 
  initiator of EMT. Menke reported that pancreatic cancer cell 
lines cultured on collagen I have a reduced capacity to cluster 
E-cadherin at points of cell–cell contact and have a more 
mesenchyme-like morphology. Menke postulated an EMT path-
way where collagen induces both the recruitment of FAK to cad-
herin adhesion complexes and the phosphorylation of β-catenin. 
Phosphorylated β-catenin then translocates to the nucleus, acti-
vating EMT target genes. Conceptually, this may be similar to 
work by Mina Bissell describing the capacity of mechanical 
forces or the shape of the cell to initiate EMT.
Figure 1.  Signaling events during EMT. The major signaling events that 
were reported in the meeting are summarized. Cleavage of E-cadherin 
(yellow) by MMP-3 resulted in activation of Snail1 through ROS. Snail1 
  localization to the nucleus is controlled by phosphorylation of a nuclear 
  export motif and a proteosomal degradation motif, which are each phos-
phorylatable by GSK-3β. An ILK-responsive element in the Snail1 pro-
moter binds PARP-1. Snail1 expression is inhibited by the MTA3–NuRD 
  chromosomal rearrangement complex, acting downstream of the activated 
estrogen receptor. Repression of E-cadherin by Snail1, Twist, or other re-
pressors leads indirectly to expression of vimentin and other mesenchymal 
gene products, partly because of β-catenin/Tcf–Lef1 activation. FOX-C2, 
as well as SIP1, can also directly activate mesenchymal gene expression. 
Translocation of β-catenin to the nucleus requires BCL9-2, which itself can 
induce EMT. Abundance of β-catenin is regulated by phosphorylation-
  dependent proteosomal degradation, unless GSK-3β is silenced through 
Wnt signaling. TGF-β is known to activate this canonical Wnt pathway, but 
TGF-β also directly activates the Tcf–Lef1 transcription complex through 
  tyrosine phosphorylation of SMAD-2. The c-Met receptor tyrosine kinase, 
through the Crk adaptor, also stimulates EMT.JCB • VOLUME 172 • NUMBER 7 • 2006  976
Regulating Snail1
The Snail1 transcriptional repressor is a key EMT regulator 
(Barrallo-Gimeno and Nieto, 2005). There was much interest in 
signaling pathways converging on Snail1 production,   stability, 
and intracellular localization. Derek Radisky (Mayo Clinic,
Jacksonville, FL) reported that matrix metalloproteinase-3 
(MMP-3) activates Snail1 production in mammary cells. MMP-3
is expressed in many primary breast tumors, induces mam-
mary carcinogenesis in transgenic mice, and causes an in vitro 
EMT in mouse mammary cells (Lochter et al., 1997;   Sternlicht 
et al., 1999). Radisky reported that MMP-3 activates EMT by 
inducing the production of an alternatively spliced variant of 
Rac1, which is a small GTPase that regulates cell migration 
through control of actin polymerization (Burridge and Wenner-
berg, 2004). This splice variant, termed Rac1b, activates the 
mitochondrial production of reactive oxygen species (ROS), 
which subsequently activates Snail1 production (Radisky et al., 
2005). However, the mechanism by which MMP-3 stimulates 
alternative splicing, or how the Rac1 variant activates ROS, is 
unclear. Snail genes can be considered regulators of cell sur-
vival, adhesion, and migration, and the triggering of the EMT is 
just one of the mechanisms they use to promote cell movement 
(Barrallo-Gimeno and Nieto, 2005). Pierre Savagner (Batiment 
de   Recherche en Cancerologie, Montpellier, France) reported 
that Snail2-defi  cient mice show delayed mammary gland tubule 
growth, and precocious branching morphogenesis similar to 
that seen in the mammary gland lacking P-cadherin, which is 
a cadherin that is selectively expressed in myoepithelial cells 
(Radice et al., 1997). Snail2-defi  cient mammary gland retained 
nor  mal smooth muscle actin-staining myoepithelial cells. These 
cells lack P-cadherin, suggesting that Snail2 controls a progenitor-
like phenotype in the mammary gland through P-cadherin.
Several investigators reported new insights into the con-
trol of Snail1 expression. Shoukat Dedhar (University of British 
Columbia, Vancouver, British Columbia, Canada) reported that 
integrin-linked kinase (ILK) activates Snail1 expression. Using 
proteomic approaches, Dedhar and coworkers made the surpris-
ing fi  nding that ILK-mediated induction of Snail1 transcrip-
tion maps to a portion of the Snail1 promoter that is bound by 
poly-ADP-ribose polymerase 1 (PARP-1). PARP-1 regulates 
transcription by modifying chromatin structure and through in-
teraction with other transcription factors (Kim et al., 2005). ILK 
activation promotes PARP-1 binding to the Snail1 promoter, 
whereas siRNA ILK knockdown and drug inhibition of ILK 
  activity prevents PARP-1 from binding to the promoter. siRNA 
knockdown of PARP-1 in mesenchymally transformed PC-3 
cells inhibited Snail1 expression and stimulated E-cadherin 
  expression, suggesting the novel idea that PARP-1 itself is an 
important factor in EMT control. It is unclear whether direct 
phosphorylation of PARP-1 by ILK controls its ability to inter-
act with the Snail1 promoter. Inhibiting ILK activity with the 
small molecular inhibitor QLT0267 inhibited production of uro-
kinase type plasminogen activator and the invasion of MDA-
MB231 breast cancer cells (Nancy Dos Santos, University of 
British Columbia, Vancouver, British Columbia, Canada).
Anna Bagnato (Regina Elena Cancer Institute, Rome, 
  Italy) also reported that endothelin 1 induced EMT in ovarian 
carcinomas in in vitro and in vivo cells through a phosphoino-
sitide 3 kinase– and ILK-mediated signaling pathway, leading 
to glycogen synthase kinase-3β (GSK-3β) inhibition, Snail and 
β-catenin stabilization, and transcriptional programs that con-
trol repression of E-cadherin. Inhibition of the endothelin A re-
ceptor reversed the EMT, suppressed ILK and Snail1 expression, 
and restored E-cadherin expression. Snail1 represses E- cadherin 
expression by binding to three independent E-boxes in the cad-
herin promoter. Snail1 prevents E-cadherin expression through 
at least two pathways, one dependent on class I histone deacet-
ylases and the other independent of it (Antonio Garcia de 
  Herreros, Universitat Pompeu Fabra, Barcelona, Spain).
Snail transcription is regulated by the estrogen receptor 
(ER; Paul Wade, National Institute of Environmental Health 
Sciences, Research Triangle Park, NC). ER is an EMT inhibitor 
and is critical in maintaining the epithelial status of normal 
breast cells. Wade reported that MTA3, which is a component 
of the Mi-2–NuRD transcriptional repressor complex, is an 
ER-responsive gene, and its expression correlates well with ER 
expression in primary breast tissue samples. Wade reported that 
MTA3 binds to the Snail1 promoter and inhibits Snail1 tran-
scription (Fujita et al., 2003). Because expression of the ER is a 
marker for good breast cancer prognosis, the observation that 
ER is an EMT inhibitor provides further evidence in support of 
a role for EMT in oncogenesis.
Snail1 levels can also be controlled posttranslationally, 
and Garcia de Herreros and Hung both reported that Snail1 is a 
phosphoprotein. Garcia de Herreros reported that Snail1 phos-
phorylation prevents its nuclear accumulation and inhibits its 
ability to activate EMT (Dominguez et al., 2003). Hung reported 
that Snail1 is phosphorylated by GSK-3β on two distinct motifs. 
Phosphorylation of two serines in the fi  rst motif directs Snail1 
ubiquitination and proteolytic destruction. Phosphorylation of 
four serines on the second motif directs nuclear export. Muta-
tion of all six GSK-3β phosphorylation sites increased the half-
life of the Snail1 protein and ensured that it was constitutively 
nuclear. Consistent with a role for Snail1 phosphorylation in 
EMT, expression of Snail1 that could not be phosphorylated 
caused a loss of E-cadherin production and an EMT-like mor-
phological change in human tumor lines (Zhou et al., 2004). 
Jim Woodgett (Samuel Lunenfeld Research Institute, Toronto, 
  Ontario, Canada) described an important role for GSK-3β in 
controlling embryonic stem cell differentiation and the mainte-
nance of pluripotency.
EMT in embryogenesis and adults
During embryogenesis, the neural crest develops from a small 
portion of the dorsal neural tube (Huang and Saint-Jeannet, 
2004; Newgreen and McKeown, 2005). After an EMT, neural 
crest cells migrate away from the neural tube and differentiate 
into bone, smooth muscle, peripheral neurons and glia, and me-
lanocytes. Don Newgreen (Murdoch Children’s Research Institute, 
Melbourne, Australia) reported that the Sox transcription 
factors control this EMT and subsequent migration. Using an 
electroporation system that delivers Sox genes to cells on one 
side of the neural tube in living chicken embryos, Newgreen re-
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to induce EMT and activate migration away from the neural 
tube while suppressing terminal differentiation. This migratory 
capacity was conferred to all cells of the neural tube, indicating 
that Sox expression was overriding inhibitory signals that nor-
mally restrict neural tube EMT to cells of the neural crest.
Nelly Auersperg (University of British Columbia, Van-
couver, British Columbia, Canada) provided evidence that EMT 
occurs in the ovaries of adult women. The mature mammalian 
ovary is enveloped by the ovarian surface epithelium (OSE), 
and the bulk of ovarian carcinomas arise from these cells. As a 
result of wound repair after egg extrusion, OSE cells are trapped 
in the ovarian follicle or stroma of postovulatory ovaries. 
Dr. Auersperg presented evidence showing that normal human 
OSE cells have a strong propensity to undergo EMT in vitro and 
in vivo in response to growth factor stimulation and alteration 
in their extracellular matrix. Auersperg suggested that normal 
OSE trapped within the ovary may undergo EMT as a means of 
maintaining ovarian homeostasis.
Cell adhesion and EMT
A defi  ning feature of EMT is a reduction in E-cadherin levels 
and a concomitant production of N-cadherin. Cadherins are 
transmembrane proteins whose homotypic interaction between 
neighboring cells creates adherens junctions (Gumbiner, 2005). 
Alteration of cadherin-based adhesion has a key role in modu-
lating development and organogenesis. At the cell membrane, 
cadherin proteins are found as homodimers tethered to the actin 
cytoskeleton by a multiprotein complex that includes α-, β-, 
and p120-catenin.
To characterize the physical forces underlying cadherin-
based adhesion, Jean-Paul Thiery (Institut Pasteur, Paris, 
France) reported on an elegant system designed to measure the 
force necessary to separate two cells that are adhered solely to 
each other (Chu et al., 2004, 2005). Thiery reported that the 
  development of intercellular adhesion by N- or E-cadherin is a 
two-step process. The fi  rst step relies on interactions between 
the cadherins on the surface of adjacent cells. This interaction 
takes 30 s to develop and requires a force of  10 nanoNewtons 
to break apart. The second step, which takes up to 30 min to 
maximize, strengthens the initial interaction and requires  200 
nanoNewtons to separate it. This strengthening depends on 
Rac- and Cdc42-mediated induction of actin polymerization, 
presumably to anchor the cell surface cadherins to the cytosol. 
Thiery also reported that four times more force is required to 
separate adhesions between E-cadherin molecules compared 
with N-cadherin ones. In addition, there is no detectable inter-
action strength between E- and N-cadherin. This supports the 
current EMT paradigm, where the presence of E-cadherin in 
epithelial cells allows for greater cell–cell adhesive strength 
compared with that of the N-cadherin–expressing mesenchyme. 
Moreover, the minimal adhesive interaction between E- and 
N-cadherin would be predicted to allow an N-cadherin–expressing 
cell to migrate through a layer of E-cadherin–expressing cells.
Alpha Yap (University of Queensland, Brisbane, Australia)  
reported evidence that E-cadherin clustering at cell–cell 
junction sites requires dynamic microtubules. Yap reported 
visual evidence that the plus ends of microtubules terminate in 
E-cadherin puncta and that agents that block dynamic plus ends 
inhibit the ability of cells to concentrate cadherin at cell–cell 
contacts. This suggests that the actin and microtubule cytoskel-
etons both serve to anchor E-cadherin adhesions. This would 
contrast cadherin adhesions to integrin-containing focal adhe-
sions because microtubule association with focal adhesions 
triggers their disassembly (Ezratty et al., 2005).
Mina Bissell (Lawrence Berkeley National Labora-
tory, Berkeley, CA) described data suggesting that cell shape 
changes brought about by the destruction of the basement mem-
brane cause EMT. She then described a model of branching 
morphogenesis of the mammary gland and showed data to sup-
port a transient EMT at the tip of the branching structures. This 
was demonstrated by the activation of the vimentin promoter 
(visualized by a GFP reporter) at the branch tip. Bissell went 
on to describe studies that provided an understanding of how 
branching structures are created. She used engineered matrices 
and biomaterials to show that the architecture of the created ves-
sel in collagen gels can determine where and how branches are 
  created. Although the role of cell geometry in growth (Folkman 
and Moscona, 1978; Chen et al., 1997), apoptosis (Chen et al., 
1997), and metabolic regulation (Bissell et al., 1977) has been 
known for decades, the molecular pathways that link cell shape 
to these events, and also to EMT, are only now beginning to be 
elucidated (Weaver et al., 2002; Paszek et al., 2005; Radisky 
et al., 2005). The orientation of a cell to its growth substrate 
may also regulate EMT. Marcia McCoy and Calvin Roskelley 
(University of British Columbia, Vancouver, British   Columbia, 
Canada) reported that overexpression or mislocalization of the
apical marker podocalyxin destabilized cell polarity in vitro, 
which may explain why podocalyxin overexpression is an 
  independent marker of in vivo breast carcinoma progression 
(Somasiri et al., 2004).
EMT in cancer
The occurrence of EMT during tumor progression allows benign 
tumor cells (i.e., ones that are noninvasive and nonmetastatic) 
to acquire the capacity to infi  ltrate surrounding tissue and to 
  ultimately metastasize to distant sites. The pathological staging 
of tumors supports this paradigm. The most compelling evidence 
for the involvement of EMT in oncogenesis is the ability of mul-
tiple EMT regulators to enhance tumor formation and/or metas-
tasis (Thiery, 2002). For example, expression of Snail1 increases 
the aggressiveness of experimentally induced breast tumors, and 
high Snail1 expression correlates with an increased risk of tumor 
relapse and poor survival rates in human breast cancer (Moody 
et al., 2005). Loss of E-cadherin is a hallmark of metastatic car-
cinoma (Cavallaro and Christofori, 2004), and proteomic analy-
sis of breast cancer reveals that circulating mammary tumor 
cells, or those found as micrometastases, show evidence of mes-
enchymal conversion (Willipinski-Stapelfeldt et al., 2005). The 
EMT meeting added to the growing list of EMT regulators that 
control some aspect of oncogenesis, which includes MMP-3, 
BCL9–2, EGFR, Met, Goosecoid, Kaiso, TGF-β, FOXC2, 
GSK-3β, Smad-3, Pez, Snail1, Snail2, and ILK (Table I).
However, there remains some controversy in the cancer 
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transformation of a normal cell into a cancerous cell or a non-
invasive tumor into a metastatic tumor is truly an EMT (Tarin 
et al., 2005). Skepticism about the role of EMT in cancer stems 
from the apparent rarity of the EMT–like morphological changes 
that are observed in primary tumor sections, and also from the 
observation that metastases appear histologically similar to the 
primary tumor from which they are derived. Of central impor-
tance, therefore, is the direct visualization of EMT during tumor 
progression. Garcia de Herreros used a new Snail1 antibody 
that is suitable for mouse and human immunohistochemistry 
(EC3) to show that Snail1 protein is expressed specifi  cally at 
the invading front of colorectal tumors. Snail antibodies have 
been diffi   cult to use in immunohistochemistry, and Karl-
  Friedrich Becker (Technical University of Munich, Munich, 
Germany) used another new Snail1 antibody (Sn9H2; Rosivatz 
et al., 2005) to demonstrate nuclear Snail1 in gastric, mammary, 
and endometrial tumors. Richard Bates reported that integrin 
αvβ6 is specifi  cally expressed at the invading edge of colorectal 
cancer xenografts. Thomas Brabletz (University of Erlangen, 
Erlangen, Germany) reported that tumor cells at the invading 
edge of colorectal carcinomas have nuclear β-catenin and loss 
of E-cadherin. Nuclear localization of β-catenin is frequently 
used as an EMT marker, and nuclear β-catenin is a marker for 
a poor prognosis in colorectal cancer. The ability of EMT 
  markers to identify a subset of tumor cells raises the possibility 
that EMT could be associated with the maintenance of cancer 
stem cells. Brabletz reported that invading cells with nuclear 
β-catenin also express the stem cell markers hTert and survivin, 
possibly implicating EMT in cancer stem cell maintenance 
(Brabletz et al., 2005). The presence of EMT markers at the 
 tumor–host interface, but not in the bulk tumor, is strong evidence 
that EMT occurs during tumor development and that it regulates 
invasiveness and tumor aggressiveness.
The histological similarity of secondary, metastasis-
  derived tumors to the primary tumor indicates that EMT-
  mediated metastatic development must be followed by a reverse 
MET to allow colonization of secondary sites. Brabletz reported 
that metastases derived from tumors originally expressing nu-
clear β-catenin were found to reexpress E-cadherin, and their 
β-catenin became cytoplasmic, which is suggestive of a MET 
(Brabletz et al., 2001). Similarly, Christine Chaffer (Bernard 
O’Brien, Institute of Microsurgery, Melbourne, Australia) re-
ported that variants of the metastatic T24/TSU-Pr1 bladder car-
cinoma line that were selected for enhanced metastatic potential 
have more epithelial markers (E-cadherin and keratins) than 
their less metastatic counterparts, but continue to express some 
mesenchymal markers (vimentin and MMPs). This ability of 
cells to express attributes of both epithelial and mesenchymal 
phenotypes was referred to by Savagner as a “metastable pheno-
type” (Fig. 2). Consistent with this idea, Savanger reported 
that Rac distribution can be found with both epithelial-like 
(  adherens junctions) and mesenchyme-like (lamellopodia) pat-
terns during the migration of cohesive epithelial cells, and prob-
ably during tumor invasion as well. Metastability is consistent 
with the expression of stem cell markers in colorectal cells un-
dergoing EMT and suggests that such plasticity may be found in 
progenitor cells in various organs. This plasticity could also be 
an explanation for the diffi  culty in observing EMT in cancer 
  development; acquisition of mesenchymal characteristics may 
be transitory and undergo a reversal during later tumorigenesis.
Robert Weinberg (Whitehead Institute, Cambridge, MA) 
reported that three transcription factors regulating develop-
mental EMT—Twist, Goosecoid, and FOXC2—have important 
roles in metastasis. Each of these gene products enhances me-
tastasis in experimental mouse models and is highly expressed 
in primary human tumors and metastases. Twist is a basic helix-
loop-helix transcription factor that was originally identifi  ed 
as a D. melanogaster EMT activator (Castanon and Baylies, 
2002). Weinberg reported that Twist expression is suffi  cient 
to induce an in vitro EMT in breast cells and that Twist inac-
tivation inhibits metastasis development in vivo (Yang et al., 
2004). Goosecoid is a homeobox transcriptional repressor that 
marks the Spemann organizer in vertebrate gastrulation and is 
one of the fi  rst identifi  ed regulators of embryological patterning 
(De Robertis et al., 2001). Both Twist and Goosecoid regulate 
FOXC2, which is a transcription factor of the FOX family of 
forkhead helix-turn-helix DNA-binding proteins that regulates 
EMT and organ development in multiple tissues (Carlsson and 
Mahlapuu, 2002). Twist, Goosecoid, and Snail1 all repress 
E-cadherin and induce FOXC2; they also enhance cell migra-
tion in vitro and metastatic potential in vivo. It is not yet known 
whether these three genes regulate individual or overlapping 
pathways of EMT and metastases. Importantly, FOXC2 also di-
rectly up-regulated mesenchymal gene transcription, rather than 
causing an EMT through E-cadherin repression.
Frans van Roy and Geert Berx (Ghent University, Ghent, 
Belgium) reported on the identifi  cation of a series of novel tar-
get genes of the E-cadherin repressors Snail1 and SIP1/ZEB2 
that control the establishment of junctional complexes, interme-
diate fi  lament networks, and the actin cytoskeleton (De Craene 
et al., 2005). They also showed some direct effects on mesen-
chymal factor transcription via these pathways. Christine Gilles 
(University of Liege, Liege, Belgium) reported that vimentin 
Figure 2.  The metastable cell phenotype. Several studies have identiﬁ  ed a 
hybrid cell showing both epithelial and mesenchymal traits. These cells are 
summarized here, in conjunction with their epithelial and mesenchymal 
counterparts. The term metastable was introduced at the meeting by Pierre 
Savagner, who showed evidence of epithelial and mesenchymal Rac local-
ization within the same cells. Similar scenarios of hybrid cells were shown by 
Chaffer (metastasis-derived T24 human bladder carcinoma cells) and Thomp-
son (EGF-treated PMC42 human breast cancer cells). Coexpression of mixed 
lineage traits within the same cell may be consistent with the stem cell–like 
proﬁ  les reported by Brabletz in colon carcinoma cells at the invasive front.EPITHELIAL–MESENCHYMAL TRANSITION (EMT) • LEE ET AL. 979
transcription was activated by SIP1/ZEB2, as well as a Tcf–
β-catenin complex.
EMT in ﬁ  brosis
The accumulation of fi  broblasts, excess collagen, and other 
  matrix components at sites of chronic infl  ammation lead to scar 
tissue formation and progressive tissue injury. These fi  broblasts 
derive from the bone marrow, but also arise from an EMT of 
cells at injury sites (Kalluri and Neilson, 2003; Neilson, 2005). 
EMT is likely involved in the progressive fi  brotic diseases of the 
heart, lung, liver, and kidney.
Eric Neilson (Vanderbilt University, Nashville, TN) pre-
sented work using fi  broblast-specifi   c protein 1 (FSP1) as a 
marker for EMT that occurs during fi  brosis (Iwano et al., 2002). 
FSP1-positive cells appear during kidney fi  brosis and in IgA 
nephropathy; increased expression of FSP1 correlates with the 
prognosis and extent of fi  brosis (Nishitani et al., 2005). The ab-
lation of FSP1 cells attenuates fi  brosis and collagen deposition, 
indicating a causal role for these cells in fi  brotic disease (Iwano 
et al., 2001). Kidney FSP1-positive cells derive from two 
sources; from the bone marrow and from an EMT at sites of 
 renal  fi  brosis (Iwano et al., 2002). Inactivation of FSP1 with 
a LacZ “knock in” mouse produced fi  broblasts that were less 
motile in wound healing assays and had impaired angiogenesis 
in an aortic ring outgrowth model. Neilson also introduced stud-
ies on the FSP1 promoter and reported the identifi  cation a new 
zinc fi   nger protein, fi   broblast transcription factor 1, which 
binds in the FSP1 promoter. Fibroblast transcription factor 1 
also up-regulates Twist and Snail1 and suppresses β-catenin, 
E-cadherin, and ZO-1 during EMT, indicating that it may be a 
key regulator of the EMT transcriptome.
Raghu Kalluri (Harvard University, Boston, MA) intro-
duced the novel concept of endothelial–mesenchymal transi-
tion, which is probably an important process in TGF-β1–mediated 
cardiac fi  brosis. Kalluri also reported that an inhibitor of TGF-β 
signaling, bone-morphogenic protein 7 (BMP7), could inhibit 
cardiac fi  brosis in two mouse models of this disease. BMP7 be-
longs to the BMP family of TGF-β growth factors, and has a 
specifi  c role as a morphogen during liver development. Kalluri 
also discussed the functional interconnection between EMT and 
angiogenesis, suggesting that angiogenesis inhibition could be 
therapeutic for fi  brosis as well as cancer. Michael Zeisberg 
(Harvard University, Boston, MA) reported that BMP7 can in-
hibit fi  broblast migration and prevent fi  brotic disease in mouse 
models of liver fi  brosis.
Emerging concepts and future directions 
of EMT
The detection of EMT in vivo during disease progression in 
adult organisms remains one of the central challenges of EMT 
physiology. Pioneering work by Iwano et al. (2002) established 
that fi  brosis involves EMT, and this approach has been extended 
to include the formation of metastatic tumor cells (Xue et al., 
2003). Evidence of EMT markers at the leading edge of invad-
ing tumors was provided by Bates (integrin αvβ6), Garcia de 
Herreros (using a new Snail1 antibody), and Brabletz (nuclear 
β-catenin), and these new fi  ndings were some of the highlights 
of the meeting, strongly suggesting an important role for EMT 
in driving tumor invasion and metastasis.
Because it is now possible to visualize the movement and 
morphology of individual tumor cells in real-time in a living 
  animal (Condeelis and Segall, 2003), the examination of EMT 
in real-time is a possibility for the future. The detailed molecular 
studies of many investigators at the EMT meetings will hope-
fully provide additional markers for this task (Table I). These 
markers may allow further investigation into the role of metasta-
bility in cancer. Metastability indicates the existence of cells 
with features of both epithelial and mesenchymal cells. This 
concept is consistent with the sequential steps of junctional dis-
solution that were described by Thiery (Thiery and Huang, 
2005) and is gaining momentum through the accumulation of 
evidence in favor of such hybrid states. The predominantly epi-
thelial, yet somewhat mesenchymal, phenotype of highly ag-
gressive and metastatic bladder cancer cells presented by Chaffer 
reinforces the potential of many cancer cells for plastic differen-
tiation. In addition, Savagner showed evidence of both epithelial 
and mesenchymal patterning of Rac in epithelial cells that were 
induced to migrate. The importance of MET or other partial loss 
of mesenchymal markers in the successful growth of metastases 
could add further opportunities for therapies that block metastases. 
The possibility that softer boundaries exist between epithelial 
and mesenchymal tumor cells and the possibility of hybrid cells 
may help explain the current lack of robust clinical evidence for 
EMT as a metastasis mediator (Tarin et al., 2005).
Most importantly, the meeting witnessed the emergence 
of EMT as a target for drug development in cancer and fi  brosis. 
For example, BMP7 mimetics antagonize TGF-β–driven EMT 
in fi  brotic kidney and heart and inhibit disease development. 
In addition, small molecule ILK inhibitors inhibit Snail1 produc-
tion, induce E-cadherin expression, and inhibit invasion. Also 
discussed at the meeting was the possibility that angiogenesis, 
EMT, fi  brosis, and cancer have common regulatory pathways 
and that the angiogenesis inhibition may be useful in both fi  bro-
sis and cancer. The involvement of ILK in angiogenesis, EMT, 
fi  brosis, and cancer suggest that ILK inhibition may be one 
  useful therapy. In addition, EMT could be used as a functional 
screen for novel anticancer agents, a strategy that led to the 
identifi  cation of motuporamine (Calvin Roskelley). Motupora-
mine was derived from a library of marine invertebrate com-
pounds and inhibits in vitro invasion and migration by activating 
the Rho GTPase and stimulating actin stress fi  ber formation. 
Continued identifi  cation of new EMT inhibitors holds the prom-
ise of novel cancer and fi  brosis treatment options.
We anticipate considerable progress in this fi  eld in the 
year leading up to the 2007 EMT meeting, which is planned 
to take place in Montpellier, France (http://www.mtci.com.au/
temtia.html), building on the current exponential trend of EMT 
observations in numerous cellular systems of physiological and 
pathophysiological importance.
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